Seres Therapeutics Inc.
(NASDAQ:MCRB) on Wednesday reported topline results from an investigator-sponsored trial evaluating SER-155 in patients with immune-related enterocolitis (irEC), with most participants achieving a steroid-free clinical response after treatment. irEC is an inflammatory complication of immune checkpoint inhibitors.
The findings also showed favorable safety and biomarker data, supporting the continued development of the live biotherapeutic candidate.
Read Also: Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash SER-155 Meets Primary Endpoint The 15-patient trial evaluated whether SER-155 could reduce gastrointestinal inflammation and diarrhea without the use of systemic immunosuppressive therapies, which are currently recommended under clinical guidelines but can increase infection risk, cause metabolic complications, and potentially interfere with ongoing cancer treatment.
By Day 15, 12 of 15 participants, or 80%, achieved the study's primary endpoint of an immunosuppressive-free clinical response, defined as at least a one-grade improvement in diarrhea symptoms without corticosteroids or biologic immunomodulators.
